文献速递主动脉疾病

II级钝性胸主动脉损伤的治疗结局

Outcomes in Grade II Blunt Thoracic Aortic Injury.
PubMed 文献 · Ann Vasc Surg · 2026-09-30

基于主动脉创伤基金会2014–2025年数据,回顾性分析114例II级钝性胸主动脉损伤患者,非手术治疗占36.8%、TEVAR占62.3%、开放修复占0.9%。非手术与TEVAR组在住院时长、呼吸机天数、院内死亡、30天死亡及主动脉相关院内死亡上均无显著差异,TEVAR组损伤更大更广泛但更年轻。

要点

  • II级钝性胸主动脉损伤中,TEVAR相较非手术治疗未见30天死亡率获益。
  • 选择TEVAR者损伤更大更广泛,非手术者更常合并颅内出血或挫伤。
  • 两组人口学特征不均衡,TEVAR组显著更年轻,需长期随访与成本效果研究。

核心结论

  • 在II级钝性胸主动脉损伤患者中,TEVAR相较非手术治疗未提供30天死亡率获益,与2026年指南更新推荐非手术治疗一致。

研究设计与样本

  • 回顾性分析主动脉创伤基金会数据库2014至2025年数据,按治疗策略比较人口学与结局。
  • 共纳入114例II级损伤,非手术治疗36.8%、TEVAR 62.3%、开放修复0.9%。

主要发现

  • 非手术与TEVAR组在住院时长(p=0.832)、呼吸机天数(p=0.933)、院内死亡(p=0.177)、30天死亡(p=0.534)及主动脉相关院内死亡(p=1.00)上均无显著差异。
  • 选择TEVAR的损伤更大且解剖更广泛,非手术患者更常合并颅内出血或挫伤。

临床怎么用

  • II级钝性胸主动脉损伤可考虑非手术治疗,TEVAR未见短期死亡率优势。
  • 治疗决策需结合损伤解剖特征与合并伤,尤其颅内出血或挫伤情况。

局限性

  • 两组人口学特征不均衡,TEVAR组显著更年轻。
  • 为回顾性数据库分析,需长期随访与成本效果研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: 2011 Society for Vascular Surgery guidelines recommend surgical management for all > grade I blunt thoracic aortic injuries (BTAI). An update to these guidelines in 2026 recommends nonoperative management (NOM) for grade II injury. Previous work from the Aortic Trauma Foundation (ATF) database has combined grade I and II BTAI for analysis. We sought to analyze outcomes specifically for grade II injuries to determine if current outcomes represented in the ATF are in line with guideline updated NOM of grade II injuries. METHODS: ATF data from 2014 to 2025 was retrospectively analyzed for demographics and outcomes based on treatment strategy. Outcomes of 30-day mortality, hospital length of stay, ventilator days, in-hospital mortality, and aortic related in-hospital mortality were determined for patients with grade II injuries with outcomes stratified for NOM vs TEVAR. Aortic injury anatomic characteristics, concomitant traumatic injuries, time from admission to repair, and procedural and access related complications were also compared between groups. RESULTS: There were 114 grade II injuries with NOM in 36.8%, TEVAR in 62.3%, and open repair in 0.9%. Patients with grade II BTAI with NOM vs TEVAR had no significant differences in hospital length of stay (p=0.832), ventilator days (p=0.933), in-hospital mortality (p=0.177), 30-day mortality (p=0.534), or aortic related in hospital mortality (p=1.00). Injuries selected for TEVAR were larger and anatomically more extensive, while NOM patients more often had intracranial hemorrhage or contusion; ten TEVAR patients (14.1%) were treated after failure of medical management, with no deaths in this subgroup. CONCLUSIONS: In agreement with updated 2026 guidelines, we found that TEVAR provides no short-term 30-day mortality benefit over NOM in patients with grade II BTAI. However these groups were demographically disparate with the TEVAR group significantly younger than NOM patients. This data should spur longer term follow-up and cost effectiveness studies for management of grade II BTAI.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Willis S, Jenkins PD, Andujo V, et al. Outcomes in Grade II Blunt Thoracic Aortic Injury. Ann Vasc Surg. 2026. PMID: 42815850. doi:10.1016/j.avsg.2026.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。